FDA Grants Priority Review to Sarclisa for Multiple Myeloma
Sarclisa was granted a priority review by the Food and Drug Administration for patients newly diagnosed with multiple myeloma who are ineligible for blood transplants.
United States Dietmar Berger Drug Administration American Society Of Clinical Oncology National Cancer Institute Clinical Oncology
Source: curetoday.com